Results 121 to 130 of about 29,641 (245)

Data‐Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño   +6 more
wiley   +1 more source

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

open access: yesMed Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng   +14 more
wiley   +1 more source

The ion channel CALHM6 controls bacterial infection-induced cellular cross-talk at the immunological synapse. [PDF]

open access: yesEMBO J, 2023
Danielli S   +11 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza   +6 more
wiley   +1 more source

Methods of Machine Learning-Based Chimeric Antigen Receptor Immunological Synapse Quality Quantification. [PDF]

open access: yesMethods Mol Biol, 2023
Gan J   +7 more
europepmc   +1 more source

Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract The FDA approval of Otarmeni, an AAV‐based gene therapy for biallelic OTOF‐associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circumvents damaged sensory structures, OTOF gene replacement targets a synaptic deficit in
Jazlyn A. Selvasingh, Justin R. Shinn
wiley   +1 more source

Osmotic Remodeling of Extracellular Vesicles for Precision Nanomedicine

open access: yesSmall, EarlyView.
Hypotonic lysis in bidistilled water is used to remodel B lymphocyte–derived extracellular vesicles into cargo‐depleted, structurally preserved nanovesicles. The process reduces intraluminal proteins and nucleic acids, reshapes membrane composition, and enhances tumor‐cell uptake in vitro, while allowing proof‐of‐concept reloading with exogenous agents,
Francesca Susa   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy